Log in

Best Stocks Under $10.00 for 2019

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $10.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $10.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

TapImmune logo

#1 - TapImmune

NASDAQ:MRKR
Stock Price: $2.86
Market Cap: $133.82 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.72 (274.7% Upside)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
ChemoCentryx logo

#2 - ChemoCentryx

NASDAQ:CCXI
Stock Price: $8.84
Market Cap: $534.04 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.33 (107.4% Upside)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Viking Therapeutics logo

#3 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $8.01
Market Cap: $607.01 million
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.76 (134.2% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.
Evolent Health logo

#4 - Evolent Health

NYSE:EVH
Stock Price: $9.50
Market Cap: $778.41 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.08 (79.8% Upside)
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management. Its services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Chiasma logo

#5 - Chiasma

NASDAQ:CHMA
Stock Price: $5.02
Market Cap: $220.59 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $14.00 (178.9% Upside)
Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.
Strongbridge Biopharma logo

#6 - Strongbridge Biopharma

NASDAQ:SBBP
Stock Price: $1.58
Market Cap: $85.10 million
P/E Ratio: 5.1
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.80 (710.1% Upside)
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Spring Bank Pharmaceuticals logo

#7 - Spring Bank Pharmaceuticals

NASDAQ:SBPH
Stock Price: $3.20
Market Cap: $45.80 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.00 (525.0% Upside)
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. It has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
OceanaGold logo

#8 - OceanaGold

OTCMKTS:OCANF
Stock Price: $1.96
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.25 (167.9% Upside)
OceanaGold Corporation engages in the exploration, development, and operation of mineral properties. The company operates the Didipio gold-copper mine on Luzon Island in the Philippines; the Macraes goldfield mine on the South Island of New Zealand; the Waihi gold mine on the North Island of New Zealand; and Haile gold mine located in South Carolina, United States of America. It also produces silver and other minerals. The company was incorporated in 2003 and is headquartered in Melbourne, Australia.
Veru logo

#9 - Veru

NASDAQ:VERU
Stock Price: $1.89
Market Cap: $120.97 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.42 (239.5% Upside)
Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Acasti Pharma logo

#10 - Acasti Pharma

NASDAQ:ACST
Stock Price: $2.04
Market Cap: $175.52 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.94 (240.1% Upside)
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Stemline Therapeutics logo

#11 - Stemline Therapeutics

NASDAQ:STML
Stock Price: $9.91
Market Cap: $417.14 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $25.00 (152.3% Upside)
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Arcturus Therapeutics logo

#12 - Arcturus Therapeutics

NASDAQ:ARCT
Stock Price: $8.93
Market Cap: $151.55 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.00 (101.6% Upside)
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.
Telaria logo

#13 - Telaria

NYSE:TLRA
Stock Price: $7.59
Market Cap: $346.49 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.45 (11.3% Upside)
Telaria, Inc. provides a software platform for publishers to manage and monetize video advertising in the United States. The company offers publishers with real-time analytics, data, and decisioning tools to control their video advertising business, as well as a monetization solution to optimize yield across a publisher's supply of digital video inventory. Its technology enables publishers to manage and deliver their directly sold and programmatic video inventory through a single platform. The company was formerly known as Tremor Video, Inc. and changed its name to Telaria, Inc. in September 2017. Telaria, Inc. was founded in 2005 and is headquartered in New York, New York.
Intra-Cellular Therapies logo

#14 - Intra-Cellular Therapies

NASDAQ:ITCI
Stock Price: $9.02
Market Cap: $495.14 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.83 (175.3% Upside)
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Genocea Biosciences logo

#15 - Genocea Biosciences

NASDAQ:GNCA
Stock Price: $2.25
Market Cap: $53.60 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $16.33 (625.9% Upside)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Applied Genetic Technologies logo

#16 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $2.77
Market Cap: $53.38 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.42 (348.3% Upside)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Galmed Pharmaceuticals logo

#17 - Galmed Pharmaceuticals

NASDAQ:GLMD
Stock Price: $4.37
Market Cap: $94.79 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $30.00 (586.5% Upside)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
SCYNEXIS logo

#18 - SCYNEXIS

NASDAQ:SCYX
Stock Price: $1.12
Market Cap: $68.88 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.00 (346.4% Upside)
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Agile Therapeutics logo

#19 - Agile Therapeutics

NASDAQ:AGRX
Stock Price: $1.49
Market Cap: $128.09 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.20 (181.9% Upside)
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Vivint Solar logo

#20 - Vivint Solar

NYSE:VSLR
Stock Price: $6.80
Market Cap: $804.56 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.58 (70.3% Upside)
Vivint Solar, Inc. provides distributed solar energy primarily to residential customers in the United States. It owns and installs solar energy systems through long-term customer contracts. The company also sells photovoltaic installation products, as well as solar renewable energy certificates. As of December 31, 2018, it had an aggregate capacity of 1,060.9 megawatts covering approximately 154,600 homes. The company was formerly known as V Solar Holdings, Inc. and changed its name to Vivint Solar, Inc. in April 2014. Vivint Solar, Inc. was founded in 2011 and is headquartered in Lehi, Utah.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel